Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Klaas, Heinemann"'
Autor:
Sophia von Stockum, Kerstin Becker, Anja Bauerfeind, Christian Franke, Franca Fruzzetti, Joaquim Calaf, Christoph Keck, Klaas Heinemann
Publikováno v:
Gynecological Endocrinology, Vol 39, Iss 1 (2023)
Objective To investigate safety and effectiveness of NOMAC-E2 and levonorgestrel-containing COCs (COCLNG) in users over 40.Methods In this large, observational study, new users1 of NOMAC-E2 and COCLNG were recruited in Europe, Australia, and Latin Am
Externí odkaz:
https://doaj.org/article/33f5a694105b42eb9245a96656462143
Autor:
Sophia von Stockum, Anja Bauerfeind, Kerstin Becker, Christian Franke, Franca Fruzzetti, Joaquim Calaf, Christoph Keck, Klaas Heinemann
Publikováno v:
Gynecological Endocrinology, Vol 39, Iss 1 (2023)
Objective: To investigate unintended pregnancy and changes in mood, acne, and weight in NOMAC-E2 vs levonorgestrel-containing COC (COCLNG) users under 25 years.Methods: In this large, observational study, new users (first-ever users of an eligible CO
Externí odkaz:
https://doaj.org/article/854088b95611477987ba5a0d2299b2ff
Autor:
Kerstin Becker, Klaas Heinemann, Bruno Imthurn, Lena Marions, Sabine Moehner, Christoph Gerlinger, Marco Serrani, Thomas Faustmann
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Endometriosis is a chronic disease that requires a suitable, lifelong treatment. To our knowledge, the Visanne Post-approval Observational Study (VIPOS) is to date the largest real-world, non-interventional study investigating hormonal manag
Externí odkaz:
https://doaj.org/article/c778c0d9ca2547efa8d7bde6acf4c01a
Autor:
Clare Barnett, MBBS (Hons), MPH, Anja Bauerfeind, PhD, Sophia Von Stockum, PhD, Klaas Heinemann, MD, PhD, MSc, MBA
Publikováno v:
AJOG Global Reports, Vol 2, Iss 1, Pp 100041- (2022)
BACKGROUND: Norethisterone (acetate) and levonorgestrel are marketed globally as components of combined oral contraceptives. Although guidelines recommend both as first-line combined oral contraceptives, no direct, comparative safety studies are avai
Externí odkaz:
https://doaj.org/article/d190e4bc1710405799fcc370f6a2543a
Autor:
Carol Koro, Kerstin Becker, Julia DiBello, Anja Bauerfeind, Suzanne Reed, Klaas Heinemann, Christian Franke
Publikováno v:
The European Journal of Contraception & Reproductive Health Care. 26:439-446
Objective To assess and compare the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) in NOMAC-E2 users with levonorgestrel-containing combined oral contraceptive (COCLNG) users. Study design This large, prospective, observation
Autor:
Sabine Moehner, Bruno Imthurn, Marco Serrani, Christoph Gerlinger, Lena Marions, Sophia von Stockum, Thomas Faustmann, Kerstin Becker, Klaas Heinemann
Publikováno v:
Journal of Endometriosis and Pelvic Pain Disorders. 13:229-237
Introduction: Women with endometriosis require individualized, long-term treatment. Analyzing prescription choices, medication switches, discontinuations, and breaks can describe real-world treatment patterns and optimize pathways for women. To our k
Autor:
Tanja Boehnke, Anja Bauerfeind, Lisa Eggebrecht, Camille Cellier, Jens A. Lange, Klaas Heinemann, Tessa Madden
Purpose: To compare the incidence of partial and complete expulsion for different copper intrauterine device (IUD) shapes. Materials and methods: A secondary analysis of the ongoing, prospective, non-interventional European Active Surveillance Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f92884b81f45254517e1e84c1be9042c
https://doi.org/10.21203/rs.3.rs-2041291/v1
https://doi.org/10.21203/rs.3.rs-2041291/v1
Publikováno v:
Contraception. 120:109920
To monitor pregnancy occurrence and outcomes among Nexplanon users in the United States during standard clinical practice.The Nexplanon Observational Risk Assessment (NORA) study was a large prospective cohort study conducted in the United States (US
Publikováno v:
European Journal of Obstetrics & Gynecology and Reproductive Biology. 251:212-217
Objective Dienogest (DNG) 2 mg (Visanne) was launched for endometriosis treatment in Europe in 2010. The Visanne Post-approval Observational Study (VIPOS) was designed to assess the safety of DNG 2 mg/day compared to other hormonal endometriosis trea
Publikováno v:
Contraception. :110003